Last reviewed · How we verify
NCT06141889
Pharmacokinetics Study of Azelaprag (BGE-105) in Older Adult Healthy Volunteers
Phase 1 trial testing Azelaprag in Healthy Volunteer Study in 16 participants. Completed in 2 February 2024.
26 January 2024
Quick facts
| Lead sponsor | BioAge Labs, Inc. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 16 |
| Start date | 17 November 2023 |
| Primary completion | 26 January 2024 |
| Estimated completion | 2 February 2024 |
| Sites | 1 location across New Zealand |
Drugs / interventions tested
- Azelaprag — full drug profile →
Conditions studied
- Healthy Volunteer Study — all drugs for Healthy Volunteer Study →
Sponsor
BioAge Labs, Inc. — full company profile →
Who can join
60 and older, any sex, with Healthy Volunteer Study. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a single-dose, open-label, randomized crossover and multiple-dose, open-label study to evaluate the PK of azelaprag in older adult healthy volunteers.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeting APJ drives BNIP3-PINK1-PARKIN induced mitophagy and improves systemic inflammatory bone loss.
Wang W, Wang Q, Li W, Xu H, et al · · 2025 · cited 6× · PMID 39725007 · DOI 10.1016/j.jare.2024.12.033 -
International Union of Basic and Clinical Pharmacology. CXXI. Apelin receptor pharmacology in the human cardiovascular system and emerging clinical applications.
Davenport AP, Williams TL, Nyimanu D, Macrae RGC, et al · · 2026 · PMID 41895070 · DOI 10.1016/j.pharmr.2026.100130
Verify or expand the search:
- PubMed search for NCT06141889
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Healthy Volunteer Study
Currently open trials in the same condition.
- NCT06825364 — Near-InfraRed Spectroscopy of Auricular Stimulation · NA · recruiting
- NCT07021079 — Muscle Vibration as a Countermeasure Against Hypoactivity-induced · NA · recruiting
- NCT06945614 — Exploratory Clinical Study to Assess Safety and Efficacy of Xenon Gas Inhalation to Control Neuroinflammation · Phase 1 · recruiting
Other BioAge Labs, Inc. trials
Trials by the same sponsor.
- NCT06515418 — Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with · Phase 2 · terminated
- NCT04705597 — Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 · Phase 2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06141889 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by BioAge Labs, Inc.
- Last refreshed: 23 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06141889.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing